Omicron News and Research

RSS

COVID-19, RSV, and flu vaccines remain safe and effective

The systematic review provides crucial insights into the efficacy and safety of respiratory virus vaccines, supporting evidence-based immunization practices.

3 Nov 2025

Updated COVID-19 vaccines continue to offer strong protection, research shows

Updated COVID-19 vaccines are still providing effective protection against infection, emergency department visits, hospitalization and death, according to new research published today in JAMA Internal Medicine.

27 Oct 2025

From stress to susceptibility: how COVID lockdowns shaped teen vaping risk

Teenagers who experienced higher COVID-19 stress during remote schooling were more likely to become open to trying vaping, which significantly increased their odds of using e-cigarettes and cannabis two years later. The study reveals that susceptibility, not immediate use, was the critical pathway linking early stress to later vaping behaviors.

12 Oct 2025

Children face higher risk of long COVID after reinfection

Children and adolescents were twice as likely to experience long COVID after catching COVID for the second time, compared to their peers with a single previous infection, according to a large study funded by the National Institutes of Health (NIH) and published in Lancet Infectious Diseases.

30 Sep 2025

Common diabetes drug metformin cuts long covid risk by 64 percent in UK study

A large UK-based retrospective cohort study found that initiating metformin within 90 days of COVID-19 diagnosis reduced the risk of Long COVID by 64% in overweight and obese adults. The findings suggest metformin may offer a low-cost preventive option pending confirmation from randomized trials.

8 Sep 2025

Llama-derived nanobody VHH21 destroys the spike-trimer of SARS-CoV-2

Neutralizing antibodies that merely block receptor binding are losing ground against heavily mutated SARS-CoV-2 Omicron sub-variants.

14 Aug 2025

Global Virus Network committed to the continued development of mRNA vaccines

The Global Virus Network (GVN), a coalition of leading human and animal virologists from 80+ Centers of Excellence and Affiliates in more than 40 countries dedicated to advancing pandemic preparedness, is unequivocally committed to the continued development and deployment of mRNA vaccines and the global scientific collaboration that makes such innovation possible.

12 Aug 2025

Global vaccination effort saved 2.5 million lives from SARS-CoV-2

Thanks to vaccinations against SARS-CoV-2 in the period 2020-2024 2.533 million deaths were prevented at global level, one death was avoided for every 5,400 doses of vaccine administered. The 82% of the lives saved by vaccines involved people vaccinated before encountering the virus, 57% during the Omicron period, and 90% involved people aged 60 years and older. In all, vaccines have saved 14.8 million years of life (one year of life saved for 900 doses of vaccine administered).

28 Jul 2025

New study uncovers how prior obesity impacts viral consequences

A study comparing the effects of SARS-CoV-2 infection in lean and obese primates found different long-term consequences of the virus depending on prior obesity and metabolic disease. The results, which also highlighted how widespread long COVID symptoms are in animals, were published July 24th in the open-access journal PLOS Pathogens by Charles Roberts of Oregon Health & Science University, USA, and colleagues.

25 Jul 2025

CoVerage outperforms rivals in early detection of COVID mutations

The CoVerage system monitors SARS-CoV-2 evolution, predicting variants and scoring amino acid changes to inform vaccine efficacy and public health strategies.

24 Jul 2025

Lasting COVID-19 vulnerability in childhood cancer survivors

The study finds childhood cancer survivors at higher risk for severe COVID-19, stressing the importance of tailored interventions for vulnerable populations.

8 Jul 2025

Updated COVID-19 vaccines found effective against severe illness

A new multi-state study led by the Centers for Disease Control and Prevention's (CDC) VISION Network – including Regenstrief Institute – has provided the most comprehensive assessment to date of the effectiveness of 2023-2024 COVID-19 vaccines among adults in the U.S. during the XBB and JN.1 Omicron subvariant waves.

25 Jun 2025

Gut microbe emerges as a promising tool in the fight against COVID-19

Researchers found that Akkermansia muciniphila boosts lung-specific antiviral immunity against SARS-CoV-2 in mice by modulating the gut–lung axis. This commensal gut bacterium shows promise as a potential biomarker and biotherapeutic candidate for COVID-19 and other respiratory infections.

25 Jun 2025

New COVID variant NB.1.8.1 spreads across continents amid calls for vigilance

The Global Virus Network (GVN) is closely monitoring the emergence of a newly identified SARS-CoV-2 variant, NB.1.8.1, a sublineage of the Omicron family. This variant was first identified in January 2025 and has rapidly spread across Asia and into other regions, including parts of the United States.

6 Jun 2025

Prior COVID-19 vaccination provides strong protection against emerging variants

Prior COVID-19 vaccination did not stop the immune system from mounting a protective response to the Delta and Omicron strains, though new mutation-specific antibody production dipped slightly, according to a study led by researchers at the University of Arizona Health Sciences and published in Nature Immunology.

27 May 2025

Reinfections lower long COVID risk but raise cumulative burden

A population-based study in Quebec found that healthcare workers faced a threefold higher risk of long COVID after a first infection compared to reinfections. However, the cumulative risk rose with each additional infection, especially among those with severe illness or early variants.

14 May 2025